Response Genetics, Inc Share Price

Equities

RGDXQ

US76123U1051

Biotechnology & Medical Research

Market Closed - OTC Markets 17:32:09 15/05/2023 BST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Response Genetics, Inc -.--% -.--%
Sales 2013 19.8M 1.58B Sales 2014 16.72M 1.33B Capitalization 12.28M 979M
Net income 2013 -8M -638M Net income 2014 -13M -1.04B EV / Sales 2013 1.92 x
Net cash position 2013 6.85M 546M Net Debt 2014 7.45M 594M EV / Sales 2014 1.18 x
P/E ratio 2013
-4.84 x
P/E ratio 2014
-0.9 x
Employees -
Yield 2013 *
-
Yield 2014
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
3 years
0.00
Extreme 1.0E-6
0.02
5 years
0.00
Extreme 1.0E-6
0.08
More quotes
Managers TitleAgeSince
Director of Finance/CFO 55 19/08/12
Members of the board TitleAgeSince
Director of Finance/CFO 55 19/08/12
More insiders
Date Price Change Volume

Delayed Quote OTC Markets, May 15, 2023 at 05:32 pm

More quotes
Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
More about the company